Exelixis (EXEL) Tops Q1 EPS by 2c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. WDC
9. LVS
10. NDAQ

Go back to Exelixis (EXEL) Tops Q1 EPS by 2c, Offers Guidance

Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update

May 5, 2020 4:05 PM EDT

- Total Revenue of $226.9 Million, Cabozantinib Franchise Revenue of $193.9 Million -

- GAAP Diluted EPS of $0.15, Non-GAAP Diluted EPS of $0.19 -

- Conference Call and Webcast Today at 5:00 PM Eastern Daylight Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Exelixis remained productive... More